Revelation Biosciences (FRA:56U0) Total Stockholders Equity : €8.72 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Total Stockholders Equity?

Revelation Biosciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €8.72 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Revelation Biosciences's Book Value per Share for the quarter that ended in Mar. 2024 was €5.34. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Revelation Biosciences's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.

Revelation Biosciences Total Stockholders Equity Historical Data

The historical data trend for Revelation Biosciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Total Stockholders Equity Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

2.81

-0.09

0.99

6.10

Revelation Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial								9.36	10.54	8.26	6.10	8.72

Revelation Biosciences (FRA:56U0) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Revelation Biosciences's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(8.715	-	0)	/	1.63294
	=	5.34

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Revelation Biosciences's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	8.715
	=	0.00

Revelation Biosciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (FRA:56U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

REVB:USA 56U1:Germany

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines